According to filings with the U.S. Securities and Exchange Commission, Superluminal Medicines is raising $25,679,107.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Cony Dcruz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Superluminal Medicines
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. Were pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.

To learn more about Superluminal Medicines, visit http://superluminalrx.com/

Contact:
Cony Dcruz, Chief Executive Officer
301-525-8752

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.